Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05882045 · ClinicalTrials.gov registry record · Phase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

A Phase 3 study of Obesity and Cardiovascular Diseases, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
1,800
Enrollment target
20
Study locations

NCT05882045 is a Phase 3 study of Obesity and Cardiovascular Diseases that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,800 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05882045, a Phase 3 study of Obesity and Cardiovascular Diseases, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,800 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

Conditions Studied

Obesity Cardiovascular Diseases

Interventions

  • DRUG Placebo
  • DRUG Retatrutide

Study Locations (20)

California

  • Valley Clinical Trials, Inc. - Covina
  • Neuro-Pain Medical Center - Fresno
  • Valley Research - Fresno
  • Collaborative Neuroscience Research, LLC - Los Alamitos
  • Velocity Clinical Research, Westlake - Los Angeles
  • Valley Clinical Trials, Inc. - Northridge
  • Velocity Clinical Research, Panorama City - Van Nuys

Florida

  • Indago Research & Health Center, Inc - Hialeah
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
  • Clinical Neuroscience Solutions, Inc. - Orlando
  • Charter Research - Winter Park - Orlando
  • Progressive Medical Research - Port Orange

Illinois

  • Northwestern University - Chicago
  • Great Lakes Clinical Trials - Gurnee - Gurnee
  • Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative - Springfield

Idaho

  • Elite Clinical Trials - Blackfoot
  • Humphreys Diabetes Center - Boise

Arizona

  • Central Phoenix Medical Clinic - Phoenix

Connecticut

  • Chase Medical Research, LLC - Waterbury

Hawaii

  • Pacific Diabetes & Endocrine Center - Honolulu

Trial Details

FieldValue
Enrollment Target 1,800 participants
Start Date 2023-05-30
Est. Completion 2026-05
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05882045

The ClinicalTrials.gov registry entry for NCT05882045 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (120% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05882045 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05882045 about?

NCT05882045 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease". The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

What is the current status of trial NCT05882045?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2023-05-30. Estimated completion is 2026-05.

What conditions does trial NCT05882045 study?

This clinical trial studies the following conditions: Obesity, Cardiovascular Diseases.

What interventions are being tested in trial NCT05882045?

The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).

Who is sponsoring clinical trial NCT05882045?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05882045 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Cardiovascular Diseases

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.